This 2018 review explores the pharmacological properties and therapeutic applications of low-dose naltrexone (LDN), defined as daily doses between 1 and 5 mg. LDN modulates the immune system by transiently blocking opioid receptors, leading to upregulation of endogenous opioids and reduction of pro-inflammatory cytokines via Toll-like receptor 4 (TLR4) antagonism.
